Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 417

1.

A Pharmacist-Led Intervention to Improve Gout Medication Adherence and Outcomes with Urate Lowering Therapy: A Site Randomized Trial.

Mikuls TR, Cheetham TC, Levy GD, Rashid N, Kerimian A, Low KJ, Coburn BW, Redden DT, Saag KG, Foster PJ, Chen L.

Am J Med. 2018 Nov 29. pii: S0002-9343(18)31134-3. doi: 10.1016/j.amjmed.2018.11.011. [Epub ahead of print]

PMID:
30503879
2.

Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation.

Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag KG, Gold DT, Halbout P, Jiwa F, Lewiecki EM, Pinto D, Adachi JD, Al-Daghri N, Bruyère O, Chandran M, Cooper C, Harvey NC, Einhorn TA, Kanis JA, Kendler DL, Messina OD, Rizzoli R, Si L, Silverman S.

Osteoporos Int. 2018 Oct 31. doi: 10.1007/s00198-018-4744-x. [Epub ahead of print]

PMID:
30382319
3.

Importance of Recent Fracture as Predictor of Imminent Fracture Risk.

Schnell AD, Curtis JR, Saag KG.

Curr Osteoporos Rep. 2018 Dec;16(6):738-745. doi: 10.1007/s11914-018-0487-z. Review.

PMID:
30368717
4.

Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies.

Silverman S, Langdahl BL, Fujiwara S, Saag K, Napoli N, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, Krege JH.

Calcif Tissue Int. 2018 Oct 20. doi: 10.1007/s00223-018-0485-2. [Epub ahead of print]

PMID:
30343436
5.

Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry.

Winthrop KL, Saag K, Cascino MD, Pei J, John A, Jahreis A, Haselkorn T, Furst DE.

Arthritis Care Res (Hoboken). 2018 Oct 8. doi: 10.1002/acr.23781. [Epub ahead of print]

PMID:
30295434
6.

The prevalence of overtreatment of osteoporosis: results from the PAADRN trial.

Hall SF, Wright NC, Wolinsky FD, Lou Y, Edmonds S, Roblin D, Jones M, Saag K, Cram P.

Arch Osteoporos. 2018 Sep 28;13(1):103. doi: 10.1007/s11657-018-0517-6.

PMID:
30267162
7.

Correction to: Hip fracture trends in the United States, 2002 to 2015.

Lewiecki EM, Wright NC, Curtis JR, Siris E, Gagel RF, Saag KG, Singer AJ, Steven PM, Adler RA.

Osteoporos Int. 2018 Nov;29(11):2583. doi: 10.1007/s00198-018-4685-4.

PMID:
30151621
8.

Medical Rehabilitation: Guidelines to Advance the Field With High-Impact Clinical Trials.

Bamman MM, Cutter GR, Brienza DM, Chae J, Corcos DM, DeLuca S, Field-Fote E, Fouad MN, Lang CE, Lindblad A, Motl RW, Perna CG, Reisman D, Saag KM, Savitz SI, Schmitz KH, Stevens-Lapsley J, Whyte J, Winstein CJ, Michel ME.

Arch Phys Med Rehabil. 2018 Dec;99(12):2637-2648. doi: 10.1016/j.apmr.2018.08.173. Epub 2018 Aug 24.

PMID:
30148997
9.

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.

Terkeltaub R, Saag KG, Goldfarb DS, Baumgartner S, Schechter BM, Valiyil R, Jalal D, Pillinger M, White WB.

Rheumatology (Oxford). 2019 Jan 1;58(1):61-69. doi: 10.1093/rheumatology/key245.

PMID:
30124941
10.

Opioids vs Nonopioids for Chronic Back, Hip, or Knee Pain.

Singh JA, Curtis JR, Saag KG.

JAMA. 2018 Aug 7;320(5):508. doi: 10.1001/jama.2018.6937. No abstract available. Erratum in: JAMA. 2018 Sep 25;320(12):1288.

PMID:
30088001
11.

Moving Career Development Upstream: Evaluation of a Course for Internal Medicine Trainees Contemplating Career Pathways in Academic Medicine.

Kraemer RR, Wakelee JF, Hites L, Frank SJ, Saag K, Rogers DA, Nellore A, Erdmann N, Nichols AC, Merlin JS.

South Med J. 2018 Aug;111(8):471-475. doi: 10.14423/SMJ.0000000000000844.

PMID:
30075472
12.

Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients with Gout and Renal Impairment: Phase III Placebo-Controlled Study.

Saag KG, Becker MA, Whelton A, Hunt B, Castillo M, Kisfalvi K, Gunawardhana L.

Arthritis Rheumatol. 2018 Aug 3. doi: 10.1002/art.40685. [Epub ahead of print]

PMID:
30073793
13.

Hypophosphatemia in the setting of metabolic bone disease: case reports and diagnostic algorithm.

Day AL, Morgan SL, Saag KG.

Ther Adv Musculoskelet Dis. 2018 Jul;10(7):151-156. doi: 10.1177/1759720X18779761. Epub 2018 Jun 15.

14.

Improving drug adherence in osteoporosis: an update on more recent studies.

Jaleel A, Saag KG, Danila MI.

Ther Adv Musculoskelet Dis. 2018 Jul;10(7):141-149. doi: 10.1177/1759720X18785539. Epub 2018 Jul 10. Review.

15.

Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies.

Langdahl BL, Silverman S, Fujiwara S, Saag K, Napoli N, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, Krege JH.

Bone. 2018 Nov;116:58-66. doi: 10.1016/j.bone.2018.07.013. Epub 2018 Jul 18.

PMID:
30021126
16.

A Performing Arts Intervention Improves Cognitive Dysfunction in 50 Hospitalized Older Adults.

Danila MI, Melnick JA, Mudano A, Flood K, Booth K, Kirklin K, Saag KG.

Innov Aging. 2018 Jun;2(2):igy013. doi: 10.1093/geroni/igy013. Epub 2018 Jun 18.

17.

Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions.

Balasubramanian A, Wade SW, Adler RA, Saag K, Pannacciulli N, Curtis JR.

J Bone Miner Res. 2018 Oct;33(10):1881-1888. doi: 10.1002/jbmr.3523. Epub 2018 Aug 22.

PMID:
29924418
18.

Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.

Gunawardhana L, Becker MA, Whelton A, Hunt B, Castillo M, Saag K.

Arthritis Res Ther. 2018 May 30;20(1):99. doi: 10.1186/s13075-018-1593-0.

19.

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.

Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R, Dore RK, Bilezikian JP, Saag KG.

J Clin Endocrinol Metab. 2018 Aug 1;103(8):2949-2957. doi: 10.1210/jc.2018-00163.

20.

Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout.

Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, Pineda C, Louthrenoo W, Edwards NL, Andrés M, Vargas-Santos AB, Roddy E, Pascart T, Lin CT, Perez-Ruiz F, Tedeschi SK, Kim SC, Harrold LR, McCarthy G, Kumar N, Chapman PT, Tausche AK, Vazquez-Mellado J, Gutierrez M, Pinheiro GDRC, Richette P, Pascual E, Fisher MC, Burgos-Vargas R, Robinson PC, Singh JA, Jansen TL, Saag KG, Slot O, Uhlig T, Solomon DH, Keenan RT, Scire CA, Biernat-Kaluza E, Dehlin M, Nuki G, Schlesinger N, Janssen M, Stamp LK, Sivera F, Reginato AM, Jacobsson L, Lioté F, Ea HK, Rosenthal A, Bardin T, Choi HK, Hershfield MS, Czegley C, Choi SJ, Dalbeth N.

Arthritis Care Res (Hoboken). 2018 May 25. doi: 10.1002/acr.23607. [Epub ahead of print]

PMID:
29799677

Supplemental Content

Support Center